Abstract:Recent studies indicated that oligomeric β -amyloid (A β) peptides are more neurotoxic to cells or tissues than A β monomers and fibrils even though the underlying mechanism of the A β -induced toxicity is still elusive. The discovery of inhibitors that can prevent cytotoxic oligomeric A β formation has become one of vital goals for therapeutic drug development for AD. Meanwhile, it is of fundamental importance to investigate and understand the structure of toxic A β oligomeric assembly, the mechanism of the induced cytotoxicity, the inhibitory mode of action, and the structural-activity relationship of inhibiting amyloid oligomerization. Toward this end, a series of 15 novel cyanine-derived A β peptide aggregation inhibitors have been synthesized aiming at investigating the structural-activity properties of these compounds in the role of AD treatment. Fifteen novel carbazole-based cyanine derivatives bearing various functionalized heteroaromatic electron-accepting moieties including pyridinium, benzothiazolium, quinolinium and acridinium have been synthesized for a systematic structure-activity relationships investigation as useful and potent A β peptide aggregation inhibitors. The binding affinity was characterized by dissociation constants derived from fluorescence titration of cyanine compounds against amyloid full-length A β 1-40, A β 1-42 peptides as well as A β fragments of different regions. The inhibitory effect on A β peptide aggregation was investigated with fluorescence, and transmission electron microscopy, and circular dichroism. The bio-viability was evaluated by cell-based and animal studies. Our studies further affirmed the importance of hydrophobic and Ï€-Ï€ stacking interactions for the association of this class of carbazole-based cyanines with A β peptides and fibrils. Slight structural modification alters the binding affinity to the monomeric and aggregated amyloids and hence the inhibition potency. Fifteen newly designed cyanine derivatives for studying the structural/activity properties of the A β binding and A β aggregation inhibition have been developed. Importantly, such slight structural variation also provides a means to tune the biological properties such as cytotoxicity and protection from A β- induced toxicity for potential clinical applications. Remarkably, seven non-toxic cyanine derived inhibitors for A β peptide self-aggregation are identified which shows therapeutic potential for AD treatment.

Hydrophobic Modification of Carboxyl-Terminated Polyamidoamine Dendrimer Surface Creates a Potent Inhibitor of Amyloid-β Fibrillation

Mixed Carboxyl and Hydrophobic Dendrimer Surface Inhibits Amyloid-β Fibrillation: New Insight from the Generation Number Effect.

Inhibitor discovery targeting the intermediate structure of beta-amyloid peptide on the conformational transition pathway: implications in the aggregation mechanism of beta-amyloid peptide.

Inhibitor discovery targeting the intermediate structure of β-amyloid peptide on the conformational transition pathway: Implications in the aggregation mechanism of β-amyloid peptide

Negatively Charged Hydrophobic Nanoparticles Inhibit Amyloid Β-Protein Fibrillation: the Presence of an Optimal Charge Density

Molecular Integrative Analysis of the Inhibitory Effects of Dipeptides on Amyloid β Peptide 1–42 Polymerization

Α-Helical Motif As Inhibitors of Toxic Amyloid-β Oligomer Generation Via Highly Specific Recognition of Amyloid Surface

Unexpected Function Of A Heptapeptide-Conjugated Zwitterionic Polymer That Coassembles Into Beta-Amyloid Fibrils And Eliminates The Amyloid Cytotoxicity

Targeting the Amyloid-β Fibril Surface with a Constrained Helical Peptide Inhibitor.

Synthesis and evaluation of ferrocenoyl pentapeptide (Fc-KLVFF) as an inhibitor of Alzheimer's Aβ₁-₄₂ fibril formation in vitro

Polyallylamine Binds to Aβ Amyloid and Inhibits Antibody Recognition

Self-Assembly Molecular Chaperone to Concurrently Inhibit the Production and Aggregation of Amyloid Β Peptide Associated with Alzheimer’s Disease

Self‐Assembled Peptide–Polyoxometalate Hybrid Nanospheres: Two in One Enhances Targeted Inhibition of Amyloid Β‐peptide Aggregation Associated with Alzheimer's Disease

Modulating Conformation of Aβ-Peptide: an Effective Way to Prevent Protein-Misfolding Disease

Coassembly of Macrocyclic Amphiphiles for Anti-beta-Amyloid Therapy of Alzheimer's Disease

POTENT INHIBITORS FOR OLIGOMERIC B-AMYLOID AGGREGATION

Charged Tubular Supramolecule Boosting Multivalent Interactions for the Drastic Suppression of Aβ Fibrillation

Design of a Molecular Hybrid of Dual Peptide Inhibitors Coupled on AuNPs for Enhanced Inhibition of Amyloid Β‐protein Aggregation and Cytotoxicity

Synthesis and Evaluation of Ferrocenoyl Pentapeptide (Fc-Klvff) As an Inhibitor of Alzheimer’s Aβ1–42 Fibril Formation in Vitro

Copolymer Polydopamine Nanoparticles as Multifunctional Nanoinhibitors for Modulating β-Amyloid Aggregation

A Comprehensive Insight into the Mechanisms of Dopamine in Disrupting Aβ Protofibrils and Inhibiting Aβ Aggregation